Indian Pharmas Gaining On MNCs In New Patent Era
This article was originally published in PharmAsia News
The fear that global companies would squeeze India's drug making industry has proved to be unfounded. Instead, multinational corporations have lost market shares within the past three years since new patent regulations were adopted. Losing MNCs include top 10-ranked firms such as Pfizer and GlaxoSmithKline. Gainers during the same period were led by India's Cipla and Ranbaxy Laboratories, both among India's top 10 pharmas. Some experts caution, however, that India's patent policy is still in its nascent stage. (Click here for more
You may also be interested in...
Guardant’s CEO anticipates accelerated adoption and reimbursement of its FDA-approved liquid biopsy assay and more biopharma partnerships.
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.